Sugi Predict

Sugi Predict / Compounds / Talastine

Talastine

Talastine

SCHEMBL30502

CN(C)CCn1nc(Cc2ccccc2)c2ccccc2c1=O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADRA1A P35348 9/20 0.81
▸ HRH1 P35367 9/20 0.81
▸ ADRA1B P35368 9/20 0.81
▸ HRH3 Q9Y5N1 4/20 0.70
▸ TSHR P16473 1/20 0.63
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ GLA P06280 1/20 0.55
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Talastine SCHEMBL29350005 1.00 ADRA1A (0.81) ADRA1AHRH1ADRA1BHRH3TSHR
Talastine SCHEMBL1650995 0.97 ADRA1A (0.78) ADRA1AHRH1ADRA1BHRH3TSHR
Talastine SCHEMBL13724065 0.83 HRH1 (0.58) ADRA1AHRH1ADRA1BHRH3TSHR
SCHEMBL10482471 0.82 ADRA1A (0.61) ADRA1AHRH1ADRA1BHRH3TSHR
SCHEMBL16363659 0.82 TSHR (0.64) ADRA1AHRH1ADRA1BHRH3TSHR
SCHEMBL12877772 0.81 TSHR (0.71) ADRA1AHRH1ADRA1BHRH3TSHR
Talastine SCHEMBL28086448 0.80 HRH1 (0.60) ADRA1AHRH1ADRA1BHRH3TSHR
SCHEMBL10700249 0.79 ADRA1A (0.57) ADRA1AHRH1ADRA1BHRH3TSHR
SCHEMBL8556390 0.78 ENPP1 (0.65) ADRA1AHRH1ADRA1BTSHRCYP1A2
SCHEMBL12862542 0.78 TSHR (0.66) ADRA1AHRH1ADRA1BHRH3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 611 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2014186623-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE BIOMED VALLEY DISCOVERIES (US) 2014-11-20 — — WO claimed
CN-101835749-A The indoles that replaces AUSPEX PHARAMACEUTICALS INC 2010-09-15 — — CN claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
WO-2010080577-A2 OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION AUSPEX PHARMACEUTICAL, INC. (US) 2010-07-15 — — WO claimed
WO-2010075090-A2 SCOPINE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2010-07-01 — — WO claimed
US-20100160272-A1 OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-24 — — US claimed
US-20100160271-A1 BICYCLIC MODULATORS OF H1 RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-24 — — US claimed
US-20100160347-A1 PYRIDO[1,2-a]PYRIMIDIN-4-ONE INHIBITORS OF MAST CELL DEGRANULATION AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-24 — — US claimed
US-20100152224-A1 SCOPINE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-17 — — US claimed
US-20090191183-A1 SUBSTITUTED INDOLES AUSPEX PHARMACEUTICALS, INC. (US) 2009-07-30 — — US claimed
WO-2009089234-A2 SUBSTITUTED DIBENZHYDRYLPIPERAZINES AUSPEX PHARMACEUTICALS (US) 2009-07-16 — — WO claimed
US-20090176792-A1 SUBSTITUTED DIBENZHYDRYLPIPERAZINES AUSPEX PHARMACEUTICALS, INC. (US) 2009-07-09 — — US claimed
WO-2009018280-A2 SUBSTITUTED INDOLES AUSPEX PHARAMACEUTICALS, INC. (US) 2009-02-05 — — WO claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152224-A1 SCOPINE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR CHRM3, CHRM5, CHRM2 ADRA1A 45/4885HRH1 160/4885ADRA1B 46/4885
US-20100160272-A1 OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION HRH4, HRH2, HRH3 ADRA1A 279/4885HRH1 4/4885ADRA1B 244/4885
US-20100160347-A1 PYRIDO[1,2-a]PYRIMIDIN-4-ONE INHIBITORS OF MAST CELL DEGRANULATION CMA1, CPA3, KIT ADRA1A 534/4885HRH1 31/4885ADRA1B 355/4885
US-20090191183-A1 SUBSTITUTED INDOLES CYSLTR1, LTB4R, LTB4R2 ADRA1A 180/4885HRH1 196/4885ADRA1B 132/4885
US-20090176792-A1 SUBSTITUTED DIBENZHYDRYLPIPERAZINES HRH2, HRH4, HRH1 ADRA1A 199/4885HRH1 3/4885ADRA1B 175/4885
US-20100160271-A1 BICYCLIC MODULATORS OF H1 RECEPTORS HRH2, HRH4, HRH1 ADRA1A 143/4885HRH1 3/4885ADRA1B 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.